4 completed. 4 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 2 | Completed 2 |
Follow tafamidis: new trials by email Literature Review of tafamidis trials Research Report on tafamidis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy Fx-1006A - Cardiomyopathy | Phase 2 | Completed | Pfizer | 35 | 2008-08-01 | 2013-01-11 |
| An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy Fx-1006A - Familial Amyloid Polyneuropathy, ATTR-PN | Phase 2 / Phase 3 | Completed | Pfizer | 86 | 2008-07-01 | 2012-12-17 |
| The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis Fx-1006A - Transthyretin-associated Amyloidosis With Polyneuropathy | Phase 2 | Completed | Pfizer | 21 | 2008-06-01 | 2013-01-18 |
| Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis Fx-1006A, Placebo - Familial Amyloid Polyneuropathy | Phase 2 / Phase 3 | Completed | Pfizer | 128 | 2007-01-01 | 2012-12-17 |
Amyloidosis (3) · Polyneuropathies (3) · Alzheimer Disease (2) · Amyloid Neuropathies, Familial (2) · Cardiomyopathies (1)
Pfizer (4)
France (3) · Germany (3) · United States (3) · Argentina (2) · Brazil (2) · Portugal (2) · Sweden (2) · Italy (1) · Spain (1) · United Kingdom (1)
Jeff Packman (2) · Jeff Packman, MBA (1)
PMID 31353964, PMID 32107748, PMID 27494299, PMID 29115008, PMID 30558645, PMID 23974642, PMID 24101373, PMID 25872787, PMID 28393570, PMID 28951660